Brainsway Ltd. announced that it had received interim results with respect to 26 patients from a double-blinded clinical trial being conducted at the Charite Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the Company's Deep TMS device for the treatment of multiple sclerosis (MS) patients.
The trial subjects were divided into three groups: a sham-stimulation control group, a treatment group that received high-frequency (18 Hz) left prefrontal stimulation, and an additional treatment group that received low-frequency (5 Hz) motor cortex stimulation. Each subject received a series of treatments three times per week over a period of six weeks. The effects of the treatment were evaluated over the course of the subsequent six-week period.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1430
